SCHEDULE: Driehaus Capital Management Reports 6.96% Stake in Cue Biopharma

Driehaus Capital Management LLC has disclosed beneficial ownership of 6.96% of Cue Biopharma, Inc.'s common stock, holding 292,144 shares.

Summary

• Driehaus Capital Management LLC (DCM) has filed a Schedule 13G, indicating it beneficially owns 292,144 shares of Cue Biopharma, Inc. common stock.
• This ownership represents 6.96% of the class of securities.
• The shares are held on a fully discretionary basis for two clients managed by DCM.
• DCM has shared voting power and shared dispositive power for these shares.
• The filing date is June 30, 2026, with the certification signed on August 14, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership without significant new strategic or financial information.

Positives

• Driehaus Capital Management LLC, a significant investment manager, has taken a notable stake in Cue Biopharma, potentially signaling confidence in the company's future prospects.
• The disclosure indicates active management and potential for increased institutional interest in Cue Biopharma.

Negatives

• The filing does not provide details on the specific investment strategy or the reasons behind acquiring this stake, leaving the market to speculate.
• The 0.00 sole voting and dispositive power suggests that ultimate control rests with the underlying clients, not DCM directly.

Risks

• The concentration of ownership by a single entity could lead to significant selling pressure if that entity decides to divest its position.
• As a Schedule 13G filing, it indicates passive investment, but changes in beneficial ownership can still be a precursor to activist involvement or significant market shifts.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Cue Biopharma's future performance.

Management Comments

• "The shares reported by Driehaus Capital Management LLC (DCM) are held by two clients on a fully discretionary basis in accounts managed by DCM."
• "Securities held in these clients' accounts are included in this report to reflect that DCM may have voting power and has dispositive power."
• "DLSM has the right and power with respect to more than 5% of the shares of Common Stock."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that significant institutional investment, as indicated by this Schedule 13G filing, is common in the biotechnology sector as investors seek to capitalize on potential drug development breakthroughs. However, the passive nature of this filing suggests DCM is not currently seeking to influence control.

Comparison to Industry Standards

• The 6.96% stake is a substantial holding for a single investment manager in a publicly traded biotechnology company, often indicating a belief in the company's value proposition.
• Many institutional investors in the biotech space hold similar or larger stakes in companies they believe have strong pipelines or therapeutic potential.

Stakeholder Impact

• Shareholders: May view the increased institutional ownership positively, potentially leading to increased liquidity and market interest.
• Management: May see this as validation of their strategy, but also a potential signal of increased scrutiny from institutional investors.
• Creditors: Unlikely to be directly impacted by this ownership disclosure.

Next Steps

• Driehaus Capital Management LLC will continue to manage the shares on behalf of its clients.
• Cue Biopharma, Inc. will continue its operations and development activities.

Key Dates

Keywords

Cue Biopharma, Driehaus Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Investment Management, Biotechnology